Advances in targeting cyclic nucleotide phosphodiesterases

Donald H. Maurice, Hengming Ke(UNC Lineberger Comprehensive Cancer Center), Faiyaz Ahmad, Yousheng Wang(Beijing Technology and Business University), Jay H. Chung, Vincent C. Manganiello
Nature Reviews Drug Discovery
April 1, 2014
10.1038/nrd4228
Cited by 764

Abstract

Related Papers

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
Klaus F. Rabe|British Journal of Pharmacology|2011|263
Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages
S.-L. Catherine Jin, Linda Yu-Ling Lan, Maria Zoudilova et al.|The Journal of Immunology|2005|253
Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.
W. J. Thompson, Wesley L. Terasaki, Paul M. Epstein et al.|PubMed|1979|244
High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.
R. T. MacFarland, Bruce D. Zelus, Joseph A. Beavo|Journal of Biological Chemistry|1991|222
High affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II-B
David B. Bregman, Nitai P. Bhattacharyya, C S Rubin|Journal of Biological Chemistry|1989|184